Amneal Pharmaceuticals Inc
NYSE:AMRX
Amneal Pharmaceuticals Inc
NYSE:AMRX
Price:
5.9 USD
0.51%
Updated:
Apr 29, 2024
P/E
Price to Earnings
Price to Earnings
-21.7
Current
-4.7
Median
22.9
Industry
Lower
than median
Lower
than industry value
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
P/E
=-21.7
Market Cap
/
1.8B
Net Income
-84m
All Countries
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
|
Amneal Pharmaceuticals Inc
NYSE:AMRX
|
1.8B USD | -21.7 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -5 347 888.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
698B USD | 133.1 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 47.4 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | -15 783.5 | |
| JP |
|
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
|
82T JPY | 9 733.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
352.2B USD | 8.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
332.3B USD | 910.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
186.7B GBP | 39.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
182.5B CHF | 13.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
176.8B CHF | 15.4 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/E
9.9
2-Years Forward
P/E
8.8
3-Years Forward
P/E
8.2
You don't have any saved screeners yet
